An Incredible Year for Multiple Myeloma. Highlights with Dr. Robert Orlowski, MD, PhD, MD Anderson
![An Incredible Year for Multiple Myeloma. Highlights with Dr. Robert Orlowski, MD, PhD, MD Anderson image](https://healthtree.org/images-resize?width=1000&height=1000&imageUrl=https%253A%252F%252Ffirebasestorage.googleapis.com%252Fv0%252Fb%252Fhealthtree-production.appspot.com%252Fo%252Fcommunity%25252Fpublic%25252Fshared%25252F12ff88f4-2ef2-49bc-9fb9-a51260eccb15_e8b0b81d-3d8b-4528-8e9d-7ed7f3a5d0f5.png%253Falt%253Dmedia)
An Incredible Year for Multiple Myeloma. Highlights with Dr. Robert Orlowski, MD, PhD, MD Anderson
Event Description
Dr. Robert Orlowski, MD, PhD MD Anderson Cancer Center Interview Date: December 18, 2015
This will be remembered as a banner year for multiple myeloma with the introduction of 5 new FDA-approved drugs. Dr. Orlowski gives us his take on the year with a "Top 12" from the December ASH conference in Orlando. His top picks include both clinical studies looking at combinations of different current drugs, the newly approved drugs, and beginnings of using immunotherapies in clinical practice. Learn more about the new announcements with an easy-to-understand but deep perspective from a multiple myeloma expert.
Thanks to our episode sponsor, Amgen
Schedule & Agenda
Speakers & Moderators
![The panelist Robert Orlowski, MD, PhD](https://storage.googleapis.com/crowdnews-media-library/29c6290e-bdce-460a-a35c-537c839b8de1.jpg)
Robert Z. Orlowski, M.D., Ph.D., is Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics, where he is board-certified in medical oncology. Dr. Orlowski earned his doctoral degree in molecular biophysics and biochemistry from Yale University and his medical degree from the Yale University School of Medicine. He completed his internship and residency in Internal Medicine at Barnes Hospital at the Washington University in St. Louis School of Medicine. After his fellowships in Hematology and Medical Oncology at John Hopkins Sidney Kimmel Comprehensive Cancer Center, he joined the faculty at University of North Carolina in Chapel Hill. Following that, Dr. Orlowski accepted a position at The University of Texas MD Anderson Cancer Center in 2007 to lead the Myeloma Section in the Department of Lymphoma/Myeloma. His research interests include pathobiology of, novel therapeutic targets and mechanisms of drug resistance in myeloma which are documented in hundreds of scientific articles, book chapters, and presentations at conferences. Dr. Orlowski is an investigator on numerous clinical trials, and appointed Myeloma Committee Chair for SWOG.
![The panelist Jennifer Ahlstrom](https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/community%2Fpublic%2Fshared%2FJenny%20Bio%20300x300.jpg?alt=media)
Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.
Have Any Questions?
Thank you for your interest in the event. If you have any questions, we would love to help!
Feel free to give us a call or send us a message below.
Get In Touch With Us
1-800-709-1113
Support@healthtree.org
![newsletter icon](https://static.healthtree.org/icons/newsletter-icon.png)
Get the latest thought leadership on your Acute Lymphocytic Leukemia delivered straight to your inbox
Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.